Turn Therapeutics TTRX 深 沪
交易中 08-27 10:48:35 美东时间
10.02
+0.390
+4.05%
华盛通- 最 高10.06
- 今 开9.54
- 成交量 7921股
- 最 低 9.51
- 昨 收 9.63
- 总市值 3.04亿
- 52周最高 26.50
- 市盈率 静 --
- 换手率 0.03%
- 52周最低 2.5701
- 委 比 -90.48%
- 总股本 3036.77万
- 历史最高 26.50
- 量 比 1.11
- 振 幅 5.71%
- 历史最低 2.5701
- 每 手 1
- 风险率 2.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Turn Therapeutics To Present Data On Its Interim Analysis Of Its Current Adaptive Phase 2 Study Of GX-03 In Atopic Dermatitis
Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7, 2026, to present key findings from the comprehensive interim analysis of its ongoi...
07-07 04:02
Turn Therapeutics Announces Interim Analysis Findings From First 50 Completed Subjects Enrolled In Ongoing Randomized, Double-Blind, Vehicle-Controlled Phase 2 Clinical Trial Evaluating GX-03 In Adults With Atopic Dermatitis
92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks (EASI-90); and 51.9%
06-01 20:36
Turn Therapeutics CEO to Present at Jefferies Conference
The latest update is out from Turn Therapeutics Inc ( ($TTRX) ). On May 19, 202...
05-19 20:46
Turn Therapeutics Appoints Former FDA Chief to Lead GX-03
Turn Therapeutics Inc ( ($TTRX) ) has shared an update. Turn Therapeutics Inc.,...
05-18 21:16
Turn Therapeutics Q1 EPS $(0.03) Misses $(0.02) Estimate
Turn Therapeutics (NASDAQ:TTRX) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 200 percent decrease over losses of $(0.01) per share from
05-12 04:22
Turn Therapeutics Q4 EPS $0.01
Turn Therapeutics (NASDAQ:TTRX) reported quarterly earnings of $0.01 per share.
04-01 04:39
美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
